Aveanna Healthcare Holdings Non-GAAP EPS of $0.23 beats by $0.02, revenue of $695.5M beats by $14.88M

Aveanna Healthcare Holdings (AVAH) reported Q3 Non-GAAP EPS of $0.23, beating estimates by $0.02, with revenue of $695.5M, up 11.8% Y/Y and $14.88M above expectations. The company raised its full-year 2026 revenue guidance to over $2.695B, up from $2.68B.

Original reporting
Published Nov 12, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVAH
Bullish
high confidence
Mentioned
$AVAH
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AVAHBullishMed
01

Why it matters

Earnings beat and raised guidance are likely to attract short‑term buying interest, especially from healthcare‑focused traders.

02

Market read

The earnings surprise and guidance lift make AVAH a near‑term trade candidate.

03

What to watch

Potential headwinds from reimbursement policy changes could temper upside.

Relevance 8/10Novelty 8/10Timing: post‑market release

Background

Aveanna Healthcare (AVAH) is a provider of home health and hospice services. The press release reports its Q3 2026 results.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Q3 Non-GAAP EPS of $0.23 beats expectations and FY2026 revenue guidance raised above $2.695B.

Expected impact

likely upward pressure as market prices in the earnings beat and raised guidance

Evidence & confidence

Both EPS and revenue beat, plus an upward revision to full-year guidance, are fresh primary disclosures that typically drive short‑term buying.

Market effects

May lift other home‑health and outpatient care providers as the segment shows earnings resilience.

U.S. healthcare sector could see modest gains in the afternoon session.

Limited to U.S. listed healthcare stocks; no broader macro impact.

Counterpoint

If guidance is still below consensus expectations, the beat may be priced in quickly.

Key entities

  • Aveanna Healthcare Holdings Inc.

    U.S. listed home‑health services provider.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.